Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497226 | 0.93 | TP53 (0.40) | KDM1ATP53ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6492282 | 0.90 | NPC1 (0.41) | KDM1ATP53ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6488453 | 0.90 | TP53 (0.42) | TP53SMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL6491525 | 0.86 | ALDH1A1 (0.38) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6502051 | 0.85 | SMN1; SMN2 (0.45) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6491345 | 0.83 | CYP1A2 (0.44) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6491900 | 0.82 | SMN1; SMN2 (0.58) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6502201 | 0.82 | TP53 (0.47) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6489500 | 0.79 | TP53 (0.49) | TP53SMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL6490167 | 0.78 | DGAT1 (0.35) | TP53ALDH1A1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | KDM1A 470/4885TP53 3031/4885ALDH1A1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.